MarketMoodz
Shattuck Labs Slides After SL-325 Phase 1 Readout
Shattuck Labs shares fell about 11.5% to roughly $4.05 on Monday after the company released Phase 1 data for SL-325, its DR3-targeting antibody program for inflammatory disease. Investors are now keyed to a Phase 2b readout expected in Q3 2026 and any partnership or licensing activity that could derisk the program.
Key Takeaways
- STTK fell roughly 11.5% to about $4.05 on Monday following the Phase 1 SL-325 readout.
- Phase 1 reportedly showed a favorable safety profile and receptor occupancy for SL-325.
- Shattuck expects a Phase 2b trial to begin or produce a readout in Q3 2026, setting the near-term catalyst.
- Analyst targets vary widely: Needham $17, H.C. Wainwright $18, Citigroup $7 (upgrade June 5), and Wedbush $11.
- Technicals show an RSI of ~24.11 (oversold) with the 20-day SMA ~ $5.95 and the 200-day SMA ~ $3.98; S&P 500 futures were up ~0.7% in the note's context.
People Involved
- No specific individuals mentioned
Entities Involved
- Shattuck Labs (STTK)Biotech focused on inflammation- and immune-mediated diseases; developer of SL-325
- SL-325DR3-directed antibody drug candidate for inflammatory bowel disease
- DR3 / TL1A pathwayBiological target pathway implicated in inflammatory disease (TL1A binds DR3)
- NeedhamAnalyst firm — Buy rating, $17 price target
- H.C. WainwrightAnalyst firm — Buy rating, $18 price target
- CitigroupAnalyst firm — Upgraded to Buy on June 5, $7 price target
- WedbushAnalyst firm — Outperform rating, $11 price target
- BenzingaNews source reporting the move and summarizing notes
MarketMoodz Analysis
Early-phase readouts often trigger outsized moves; Monday's roughly 11.5% drop shows the market is sorting risk vs. optionality. Phase 1 signals — a reportedly clean safety profile and receptor occupancy — reduce one binary risk (safety), but they don't guarantee efficacy. The spread between current price (~$4.05) and analyst targets (from $7 to $18) highlights how much upside is contingent on successful Phase 2b data or a strategic partnership that would validate the program and provide non-dilutive funding.
Technically and tactically, SL-325 looks oversold on a short-term basis (RSI ~24), while the 200-day SMA near $3.98 sits close to the session price, offering a potential support level. For investors, the key near-term items to watch are the precise Phase 2b timeline and protocol details, any interim biomarker or expansion cohort data, and partnership or licensing announcements — each could re-rate the stock. Remember that the reporting underlying this move relied on company notes and secondary coverage; some claims, including molecular detail and timelines, could not be independently verified, so plan position sizing and due diligence accordingly.
Source: Original Article